- Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin +12007 | First Faculty of Medicine
- Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin +12007 | Faculty of Medicine in Hradec Králové
- Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- Pregnancy Experience : Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program2016 | First Faculty of Medicine
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis2015 | First Faculty of Medicine
- Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study2016 | First Faculty of Medicine
- Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study2020 | First Faculty of Medicine
- Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE2018 | First Faculty of Medicine
- Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis2016 | First Faculty of Medicine
- No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study2017 | First Faculty of Medicine
- Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes : Results from the SELECT trial2016 | First Faculty of Medicine
- Induction therapy in lung transplantation: Initial single-center experience comparing daclizumab and antithymocyte globulin2007 | Second Faculty of Medicine
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial2013 | First Faculty of Medicine
- Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis2014 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient?2011 | First Faculty of Medicine
- Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin2007 | Faculty of Physical Education and Sport
- Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study2014 | First Faculty of Medicine
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial2014 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient ?2011 | First Faculty of Medicine
- A Randomized Trial to Assess the Impact of Early Steroid Withdrawal on Growth in Pediatric Renal Transplantation: The TWIST Study2010 | Second Faculty of Medicine
- Corticosteroid-free Kidney Transplantation Improves Growth2015 | Second Faculty of Medicine